WHO ICTRP trial

Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients…

PER-015-07 · Registro Peruano de Ensayos Clínicos (REPEC) · Not Recruiting

Key facts

Trial ID PER-015-07
Public title Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes
Scientific title PROTOCOL CLAF237A2338: MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY, WITH ACTIVE CONTROL TO COMPARE THE EFFECT OF THE TREATMENT OF 52 WEEKS WITH LAF237 50 MG BID AGAINST GLICLAZIDE UP TO 320 MG DAILY AS ADDED THERAPY IN PATIENTS WITH TYPE 2 DIABETES NOT CONTROLLED ADEQUATELY WITH MONOTHERAPY WITH…
Primary sponsor NOVARTIS BIOSCIENSES PERU S.A.,
Registry Registro Peruano de Ensayos Clínicos (REPEC)
Recruitment status Not Recruiting
Study type Interventional
Phase III
Countries India;Germany;Denmark;Slovakia;Spain;Hungary;Italy;United Kindgdom;Switzerland;Czech Republic
Conditions -E119 Non-insulin-dependent diabetes mellitus, without complications Non-insulin-dependent diabetes mellitus, without complications;E119;Non-insulin-dependent diabetes mellitus, without complications
Interventions Group name:GROUP 1 Type of group;1 N° of participants:235 Intervention(s) description:This group will be treated with LAF-237, in 50 mg tablets, at a dose of 50 mg, PO, QD, for 52 weeks + Metformin, in tablets, at a dose equal to or greater…
Registration date Apr 27, 2007
Target size 50
Secondary IDs CTRI/2008/091/000201;NCT00102466;2004-000542-20
Registry page ins.gob.pe

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations